{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T22:58:46Z","timestamp":1756076326400,"version":"3.37.3"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,17]],"date-time":"2021-12-17T00:00:00Z","timestamp":1639699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000274","name":"British Heart Foundation","doi-asserted-by":"crossref","award":["British Heart Foundation"],"award-info":[{"award-number":["British Heart Foundation"]}],"id":[{"id":"10.13039\/501100000274","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The enhanced thrombotic milieu in diabetes contributes to increased risk of vascular events. Aspirin, a key antiplatelet agent, has inconsistent effects on outcomes in diabetes and the best dosing regimen remains unclear. This work investigated effects of aspirin dose and interaction with glycaemia on both the cellular and protein components of thrombosis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A total of 48 participants with type 1 diabetes and 48 healthy controls were randomised to receive aspirin 75 or 300\u00a0mg once-daily (OD) in an open-label crossover study. Light transmittance aggregometry and fibrin clot studies were performed before and at the end of each treatment period.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Aspirin demonstrated reduced inhibition of collagen-induced platelet aggregation (PA) in participants with diabetes compared with controls, although the higher dose showed better efficacy. Higher aspirin dose facilitated clot lysis in controls but not individuals with diabetes. Collagen-induced PA correlated with glycaemic control, those in the top HbA1c tertile having a lesser inhibitory effect of aspirin. Threshold analysis suggested HbA1c levels of &gt;\u200965 mmol\/mol and &gt;\u200970 mmol\/mol were associated with poor aspirin response to 75 and 300\u00a0mg daily doses, respectively. Higher HbA1c was also associated with longer fibrin clot lysis time.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Patients with diabetes respond differently to the antiplatelet and profibrinolytic effects of aspirin compared with controls. In particular, those with elevated HbA1c have reduced inhibition of PA with aspirin. Our findings indicate that reducing glucose levels improves the anti-thrombotic action of aspirin in diabetes, which may have future clinical implications.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>EudraCT, 2008-007875-26, <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2008-007875-26\">https:\/\/www.clinicaltrialsregister.eu\/ctr-search\/search?query=2008-007875-26<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12933-021-01427-y","type":"journal-article","created":{"date-parts":[[2022,8,16]],"date-time":"2022-08-16T14:03:34Z","timestamp":1660658614000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["A randomised controlled trial to assess the antithrombotic effects of aspirin in type 1 diabetes: role of dosing and glycaemic control"],"prefix":"10.1186","volume":"20","clinical-trial-number":[{"clinical-trial-number":"2008-007875-26","registry":"10.18810\/euctr"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7822-8852","authenticated-orcid":false,"given":"William A. E.","family":"Parker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Sagar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zeyad","family":"Kurdee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fladia","family":"Hawkins","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid M.","family":"Naseem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Grant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1636-3725","authenticated-orcid":false,"given":"Ramzi A.","family":"Ajjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,12,17]]},"reference":[{"issue":"1","key":"1427_CR1","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12933-021-01212-x","volume":"20","author":"KKW Olesen","year":"2021","unstructured":"Olesen KKW, Madsen M, Gyldenkerne C, Thrane PG, Thim T, Jensen LO, B\u00f8tker HE, S\u00f8rensen HT, Maeng M. Ten-year cardiovascular risk in diabetes patients without obstructive coronary artery disease: a retrospective Western Denmark cohort study. Cardiovasc Diabetol. 2021; 20(1):23.","journal-title":"Cardiovasc Diabetol."},{"issue":"10","key":"1427_CR2","doi-asserted-by":"publisher","first-page":"2843","DOI":"10.2337\/dc14-1720","volume":"37","author":"SD de Ferranti","year":"2014","unstructured":"de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, et al. Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843.","journal-title":"Diabetes Care."},{"key":"1427_CR3","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/heartjnl-2020-316914","volume":"107","author":"WAE Parker","year":"2021","unstructured":"Parker WAE, Storey RF. Antithrombotic therapy for patients with chronic coronary syndromes. Heart 2021; 107:925\u2013933.","journal-title":"Heart"},{"issue":"43","key":"1427_CR4","doi-asserted-by":"publisher","first-page":"17597","DOI":"10.1073\/pnas.1209192109","volume":"109","author":"NS Kirkby","year":"2012","unstructured":"Kirkby NS, Lundberg MH, Harrington LS, Leadbeater PD, Milne GL, Potter CM, Al-Yamani M, Adeyemi O, Warner TD, Mitchell JA. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological production of prostacyclin in the cardiovascular system. Proc Natl Acad Sci U S A. 2012; 109(43):17597\u201317602.","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"5","key":"1427_CR5","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1161\/ATVBAHA.109.183707","volume":"29","author":"RA Ajjan","year":"2009","unstructured":"Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol. 2009; 29(5):712\u2013717.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1427_CR6","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1055\/s-0039-1701011","volume":"120","author":"W Sumaya","year":"2020","unstructured":"Sumaya W, Wallentin L, James SK, Siegbahn A, Gabrysch K, Himmelmann A, Ajjan RA, Storey RF. Impaired fibrinolysis predicts adverse outcome in acute coronary syndrome patients with diabetes: a PLATO sub-study. Thromb Haemost. 2020;120(3):412\u201322.","journal-title":"Thromb Haemost."},{"issue":"1","key":"1427_CR7","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1186\/s12933-019-0875-4","volume":"18","author":"S Seidu","year":"2019","unstructured":"Seidu S, Kunutsor SK, Sesso HD, Gaziano JM, Buring JE, Roncaglioni MC, Khunti K. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials. Cardiovasc Diabetol. 2019; 18(1):70.","journal-title":"Cardiovasc Diabetol."},{"issue":"16","key":"1427_CR8","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1056\/NEJMoa1804988","volume":"379","author":"L Bowman","year":"2018","unstructured":"Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, et al. Effects of aspirin for primary prevention in persons with diabetes mellitus. N Engl J Med. 2018;379(16):1529\u201339.","journal-title":"N Engl J Med."},{"issue":"3","key":"1427_CR9","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00125-007-0898-3","volume":"51","author":"R Ajjan","year":"2008","unstructured":"Ajjan R, Storey RF, Grant PJ. Aspirin resistance and diabetes mellitus. Diabetologia. 2008; 51(3):385\u2013390.","journal-title":"Diabetologia."},{"key":"1427_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.thromres.2017.11.013","volume":"161","author":"L Vernstrom","year":"2018","unstructured":"Vernstrom L, Funck KL, Grove EL, Laugesen E, Baier JM, Hvas AM, Poulsen PL. Antiplatelet effect of aspirin during 24\u00a0h in patients with type 2 diabetes without cardiovascular disease. Thromb Res. 2018; 161:1\u20136.","journal-title":"Thromb Res"},{"issue":"3","key":"1427_CR11","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1093\/eurheartj\/ehz425","volume":"41","author":"J Knuuti","year":"2020","unstructured":"Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C, Prescott E, Storey RF, Deaton C, Cuisset T, et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407\u201377.","journal-title":"Eur Heart J."},{"issue":"7329","key":"1427_CR12","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.324.7329.71","volume":"324","author":"Antiplatelet Trialists\u2019 Collaboration","year":"2002","unstructured":"Antiplatelet Trialists\u2019 Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002; 324(7329):71\u201386.","journal-title":"BMJ"},{"issue":"14","key":"1427_CR13","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/j.jacc.2017.08.037","volume":"70","author":"C Patrono","year":"2017","unstructured":"Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G. Antiplatelet agents for the treatment and prevention of coronary atherothrombosis. J Am Coll Cardiol. 2017;70(14):1760\u201376.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"1427_CR14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1172\/JCI103356","volume":"35","author":"CHW Leeksma","year":"1956","unstructured":"Leeksma CHW, Cohen JA. Determination of the life span of human blood platelets using labelled diisopropylfluorophosphanate. J Clin Invest. 1956; 35(9):964\u2013969.","journal-title":"J Clin Invest."},{"issue":"19","key":"1427_CR15","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1016\/j.jacc.2007.07.058","volume":"50","author":"RF Storey","year":"2007","unstructured":"Storey RF, Husted S, Harrington RA, Heptinstall S, Wilcox RG, Peters G, Wickens M, Emanuelsson H, Gurbel P, Grande P, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50(19):1852\u20136.","journal-title":"J Am Coll Cardiol"},{"key":"1427_CR16","doi-asserted-by":"publisher","first-page":"e71150","DOI":"10.1371\/journal.pone.0071150","volume":"8","author":"S Neergaard-Petersen","year":"2013","unstructured":"Neergaard-Petersen S, Ajjan R, Hvas AM, Hess K, Larsen SB, Kristensen SD, Grove EL. Fibrin clot structure and platelet aggregation in patients with aspirin treatment failure. Plos One. 2013; 8:e71150.","journal-title":"Plos One"},{"key":"1427_CR17","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1161\/ATVBAHA.107.153221","volume":"27","author":"A Carter","year":"2007","unstructured":"Carter A, Cymbalista C, Spector T, Grant P. Heritability of clot formation, morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol. 2007; 27:2783\u20132789.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"1427_CR18","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1160\/th15-06-0467","volume":"115","author":"F Franchi","year":"2016","unstructured":"Franchi F, Rollini F, Cho JR, King R, Phoenix F, Bhatti M, DeGroat C, Tello-Montoliu A, Zenni MM, Guzman LA, et al. Effects of dabigatran on the cellular and protein phase of coagulation in patients with coronary artery disease on dual antiplatelet therapy with aspirin and clopidogrel. Results from a prospective, randomised, double-blind, placebo-controlled study. Thromb Haemost. 2016;115(3):622\u201331.","journal-title":"Thromb Haemost."},{"issue":"8","key":"1427_CR19","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.1007\/s00125-014-3267-z","volume":"57","author":"K Hess","year":"2014","unstructured":"Hess K, Alzahrani SH, Price JF, Strachan MW, Oxley N, King R, Gamlen T, Schroeder V, Baxter PD, Ajjan RA. Hypofibrinolysis in type 2 diabetes: the role of the inflammatory pathway and complement C3. Diabetologia. 2014; 57(8):1737\u20131741.","journal-title":"Diabetologia."},{"issue":"1","key":"1427_CR20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12933-019-0981-3","volume":"19","author":"WAE Parker","year":"2020","unstructured":"Parker WAE, Schulte C, Barwari T, Phoenix F, Pearson SM, Mayr M, Grant PJ, Storey RF, Ajjan RA. Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels. Cardiovasc Diabetol. 2020; 19(1):3.","journal-title":"Cardiovasc Diabetol."},{"issue":"1","key":"1427_CR21","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1186\/s12933-021-01335-1","volume":"20","author":"D Yuan","year":"2021","unstructured":"Yuan D, Jiang P, Zhu P, Jia S, Zhang C, Liu Y, Liu R, Xu J, Tang X, Zhao X, et al. Prognostic value of fibrinogen in patients with coronary artery disease and prediabetes or diabetes following percutaneous coronary intervention: 5-year findings from a large cohort study. Cardiovasc Diabetol. 2021;20(1):143.","journal-title":"Cardiovasc Diabetol."},{"issue":"6","key":"1427_CR22","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1160\/th14-05-0468","volume":"112","author":"S Neergaard-Petersen","year":"2014","unstructured":"Neergaard-Petersen S, Hvas AM, Kristensen SD, Grove EL, Larsen SB, Phoenix F, Kurdee Z, Grant PJ, Ajjan RA. The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thromb Haemost. 2014; 112(6):1142\u20131150.","journal-title":"Thromb Haemost."},{"issue":"5","key":"1427_CR23","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1177\/0003319706293132","volume":"57","author":"HS Al-Barjas","year":"2006","unstructured":"Al-Barjas HS, Ariens R, Grant P, Scott JA. Raised plasma fibrinogen concentration in patients with abdominal aortic aneurysm. Angiology. 2006; 57(5):607\u2013614.","journal-title":"Angiology."},{"issue":"15","key":"1427_CR24","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1001\/archinte.167.15.1593","volume":"167","author":"JD Snoep","year":"2007","unstructured":"Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Huisman MV. Association of laboratory-defined aspirin resistance with a higher risk of recurrent cardiovascular events: a systematic review and meta-analysis. Arch Intern Med. 2007; 167(15):1593\u20131599.","journal-title":"Arch Intern Med."},{"issue":"2","key":"1427_CR25","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00109-004-0600-x","volume":"83","author":"C Watala","year":"2005","unstructured":"Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J. Increased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol Med (Berl). 2005; 83(2):148\u2013158.","journal-title":"J Mol Med (Berl)"},{"issue":"4","key":"1427_CR26","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s00125-011-2301-7","volume":"55","author":"K Hess","year":"2012","unstructured":"Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, Strachan MWJ, Price JF, Smith KA, et al. A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia. 2012;55(4):1103\u201313.","journal-title":"Diabetologia."},{"issue":"1","key":"1427_CR27","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1182\/blood-2013-04-494641","volume":"122","author":"RA Ajjan","year":"2013","unstructured":"Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, Anwar MM, Rabbani N, Thornalley PJ, et al. Diabetes is associated with posttranslational modifications in plasminogen resulting in reduced plasmin generation and enzyme-specific activity. Blood. 2013;122(1):134\u201342.","journal-title":"Blood"},{"issue":"1","key":"1427_CR28","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12933-017-0515-9","volume":"16","author":"K Kearney","year":"2017","unstructured":"Kearney K, Tomlinson D, Smith K, Ajjan R. Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. Cardiovasc Diabetol. 2017; 16(1):34.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"1427_CR29","doi-asserted-by":"publisher","first-page":"674","DOI":"10.2337\/dc18-2047","volume":"42","author":"E Gerbaud","year":"2019","unstructured":"Gerbaud E, Darier R, Montaudon M, Beauvieux MC, Coffin-Boutreux C, Coste P, Douard H, Ouattara A, Catargi B. Glycemic variability is a powerful independent predictive factor of midterm major adverse cardiac events in patients with diabetes with acute coronary syndrome. Diabetes Care. 2019;42(4):674\u201381.","journal-title":"Diabetes Care."},{"key":"1427_CR30","doi-asserted-by":"crossref","unstructured":"Parker WAE, Storey RF. Aspirin dosing in atherosclerotic cardiovascular disease: should we be more ADAPTABLE? Cardiovasc Res. 2021; in press.","DOI":"10.1093\/cvr\/cvab251"},{"key":"1427_CR31","doi-asserted-by":"publisher","first-page":"1981","DOI":"10.1056\/NEJMoa2102137","volume":"384","author":"WS Jones","year":"2021","unstructured":"Jones WS, Mulder H, Wruck LM, Pencina MJ, Kripalani S, Mu\u00f1oz D, Crenshaw DL, Effron MB, Re RN, Gupta K, et al. Comparative effectiveness of aspirin dosing in cardiovascular disease. N Engl J Med. 2021;384:1981.","journal-title":"N Engl J Med."},{"issue":"2","key":"1427_CR32","doi-asserted-by":"publisher","first-page":"404","DOI":"10.2337\/dc11-1302","volume":"35","author":"S Tehrani","year":"2012","unstructured":"Tehrani S, Antovic A, Mobarrez F, Mageed K, Lins PE, Adamson U, Wallen HN, Jorneskog G. High-dose aspirin is required to influence plasma fibrin network structure in patients with type 1 diabetes. Diabetes Care. 2012; 35(2):404\u2013408.","journal-title":"Diabetes Care."},{"issue":"14","key":"1427_CR33","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa1908077","volume":"381","author":"PG Steg","year":"2019","unstructured":"Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Ridderstrale W, et al. Ticagrelor in patients with stable coronary disease and diabetes. N Engl J Med. 2019;381(14):1309\u201320.","journal-title":"N Engl J Med"},{"issue":"23","key":"1427_CR34","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1016\/j.jacc.2016.03.529","volume":"67","author":"DL Bhatt","year":"2016","unstructured":"Bhatt DL, Bonaca MP, Bansilal S, Angiolillo DJ, Cohen M, Storey RF, Im K, Murphy SA, Held P, Braunwald E, et al. Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS-TIMI 54. J Am Coll Cardiol. 2016;67(23):2732\u201340.","journal-title":"J Am Coll Cardiol."},{"issue":"14","key":"1427_CR35","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","volume":"377","author":"JW Eikelboom","year":"2017","unstructured":"Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakovska O, Diaz R, Alings M, Lonn EM, Anand SS, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319\u201330.","journal-title":"N Engl J Med"},{"issue":"3","key":"1427_CR36","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1160\/TH11-04-0216","volume":"106","author":"G Spectre","year":"2011","unstructured":"Spectre G, Arnetz L, Ostenson CG, Brismar K, Li N, Hjemdahl P. Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thromb Haemost. 2011; 106(3):491\u2013499.","journal-title":"Thromb Haemost."},{"issue":"1","key":"1427_CR37","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1080\/09537104.2020.1714574","volume":"32","author":"WAE Parker","year":"2020","unstructured":"Parker WAE, Storey RF. Novel approaches to P2Y12 inhibition and aspirin dosing. Platelets. 2020; 32(1):7\u201314.","journal-title":"Platelets."},{"issue":"2","key":"1427_CR38","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1080\/09537104.2019.1572880","volume":"30","author":"WAE Parker","year":"2019","unstructured":"Parker WAE, Orme RC, Hanson J, Stokes HM, Bridge CM, Shaw PA, Sumaya W, Thorneycroft K, Petrucci G, Porro B, et al. Very-low-dose twice-daily aspirin maintains platelet inhibition and improves haemostasis during dual-antiplatelet therapy for acute coronary syndrome. Platelets. 2019;30(2):148\u201357.","journal-title":"Platelets."}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-021-01427-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-021-01427-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,17]],"date-time":"2022-08-17T01:03:14Z","timestamp":1660698194000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-021-01427-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,17]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["1427"],"URL":"https:\/\/doi.org\/10.1186\/s12933-021-01427-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"type":"electronic","value":"1475-2840"}],"subject":[],"published":{"date-parts":[[2021,12,17]]},"assertion":[{"value":"14 October 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This trial was approved by the National Health Service Research Ethics Service prior to commencement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RF Storey reports institutional research grants\/support from AstraZeneca, Cytosorbents and GlyCardial Diagnostics; consultancy fees from AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, CSL Behring, Cytosorbents, GlyCardial Diagnostics, Hengrui, Idorsia, Novartis, PhaseBio, Portola, Sanofi Aventis and Thromboserin; and honoraria from AstraZeneca, Bayer, Bristol Myers Squibb\/Pfizer, Intas Pharmaceuticals and Medscape. RA. Ajjan. received honoraria and educational and research support from Abbott Diabetes Care, AstraZeneca, Novo Nordisk, Eli Lilly, Bayer, Sanofi, MSD, and Boehringer Ingelheim. The other authors report no relevant disclosures.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"238"}}